Articles > ZBIO Investors Facing Lawsuits
- Rosen Law Firm reminding Zenas BioPharma investors of lead plaintiff deadline on June 16, 2025
- Levi & Korsinsky notifying investors of class action lawsuit against Zenas BioPharma
- Cohen Milstein seeking investors to lead securities fraud class action against Zenas BioPharma
- DiCello Levitt LLP filing class action lawsuit against Zenas BioPharma
- Robbins Geller Rudman & Dowd LLP offers investors with substantial losses opportunity to lead investor class action lawsuit
Zenas BioPharma investors are currently facing a series of lawsuit alerts and class action filings by various law firms, including the Rosen Law Firm, Levi & Korsinsky, Cohen Milstein, DiCello Levitt LLP, Robbins Geller Rudman & Dowd LLP, and more. These lawsuits are all tied to the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) related to the registration statement and prospectus issued during the company's initial public offering in September 2024.
Investors who purchased Zenas BioPharma securities are being reminded by the Rosen Law Firm of the upcoming lead plaintiff deadline on June 16, 2025. They may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement. Similarly, Levi & Korsinsky has also notified investors about a class action lawsuit against Zenas BioPharma, providing them with an opportunity to learn about potential recoveries under federal securities laws.
Furthermore, Cohen Milstein Sellers & Toll PLLC is actively seeking investors who bought shares in Zenas BioPharma's IPO to lead a class action lawsuit currently pending in federal court. The firm is investigating claims and encouraging shareholders with significant losses to come forward and participate in the legal process.
DiCello Levitt LLP is another law firm that has filed a class action lawsuit against Zenas BioPharma, targeting persons who acquired the company's securities during the IPO in September 2024. This lawsuit alleges violations of federal securities laws by the company, certain senior executives and directors, as well as the underwriters of the IPO.
Robbins Geller Rudman & Dowd LLP has also announced an opportunity for investors with substantial losses in Zenas BioPharma to lead an investor class action lawsuit against the company. Investors who suffered damages as a result of purchasing ZBIO securities may seek appointment as lead plaintiff until June 16, 2025.
Overall, the multiple class action lawsuits and investor alerts surrounding Zenas BioPharma highlight the legal challenges faced by investors who purchased the company's securities during its IPO. With various law firms actively pursuing claims on behalf of affected investors, the outcome of these legal proceedings could significantly impact the future of Zenas BioPharma, Inc.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
ZBIO Investors Facing Lawsuits
By KlickAnalytics Data Insights | April 24, 2025 08:00PM ET
Key Points
- Rosen Law Firm reminding Zenas BioPharma investors of lead plaintiff deadline on June 16, 2025
- Levi & Korsinsky notifying investors of class action lawsuit against Zenas BioPharma
- Cohen Milstein seeking investors to lead securities fraud class action against Zenas BioPharma
- DiCello Levitt LLP filing class action lawsuit against Zenas BioPharma
- Robbins Geller Rudman & Dowd LLP offers investors with substantial losses opportunity to lead investor class action lawsuit
Zenas BioPharma investors are currently facing a series of lawsuit alerts and class action filings by various law firms, including the Rosen Law Firm, Levi & Korsinsky, Cohen Milstein, DiCello Levitt LLP, Robbins Geller Rudman & Dowd LLP, and more. These lawsuits are all tied to the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) related to the registration statement and prospectus issued during the company's initial public offering in September 2024.
Investors who purchased Zenas BioPharma securities are being reminded by the Rosen Law Firm of the upcoming lead plaintiff deadline on June 16, 2025. They may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement. Similarly, Levi & Korsinsky has also notified investors about a class action lawsuit against Zenas BioPharma, providing them with an opportunity to learn about potential recoveries under federal securities laws.
Furthermore, Cohen Milstein Sellers & Toll PLLC is actively seeking investors who bought shares in Zenas BioPharma's IPO to lead a class action lawsuit currently pending in federal court. The firm is investigating claims and encouraging shareholders with significant losses to come forward and participate in the legal process.
DiCello Levitt LLP is another law firm that has filed a class action lawsuit against Zenas BioPharma, targeting persons who acquired the company's securities during the IPO in September 2024. This lawsuit alleges violations of federal securities laws by the company, certain senior executives and directors, as well as the underwriters of the IPO.
Robbins Geller Rudman & Dowd LLP has also announced an opportunity for investors with substantial losses in Zenas BioPharma to lead an investor class action lawsuit against the company. Investors who suffered damages as a result of purchasing ZBIO securities may seek appointment as lead plaintiff until June 16, 2025.
Overall, the multiple class action lawsuits and investor alerts surrounding Zenas BioPharma highlight the legal challenges faced by investors who purchased the company's securities during its IPO. With various law firms actively pursuing claims on behalf of affected investors, the outcome of these legal proceedings could significantly impact the future of Zenas BioPharma, Inc.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.